Taysha Historical Balance Sheet

TSHA Stock

USD 1.93 0.05 2.66%

Trend analysis of Taysha Gene Therapies balance sheet accounts such as Net Tangible Assets of 127.1 M, Non Current Assets Total of 25.2 M, Non Currrent Assets Other of 3.3 M or Other Assets of 2.3 M provides information on Taysha Gene's total assets, liabilities, and equity, which is the actual value of Taysha Gene Therapies to its prevalent stockholders. By breaking down trends over time using Taysha Gene balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Taysha Gene Therapies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Taysha Gene Therapies is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taysha Gene Therapies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

About Taysha Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Taysha Gene Therapies at a specified time, usually calculated after every quarter, six months, or one year. Taysha Gene Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Taysha Gene and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Taysha currently owns. An asset can also be divided into two categories, current and non-current.

Taysha Gene Balance Sheet Chart

At present, Taysha Gene's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 67.6 M, whereas Total Assets are forecasted to decline to about 169.8 M.

Total Assets Other Current Liab Total Current Liabilities Total Current Assets Other Liab

Total Assets

Total assets refers to the total amount of Taysha Gene assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Taysha Gene Therapies books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Taysha Gene balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Taysha Gene Therapies are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most accounts from Taysha Gene's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Taysha Gene Therapies current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taysha Gene Therapies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	16.8M	10.6M	12.2M	13.8M
Total Assets	126.3M	172.7M	198.6M	169.8M

Other Current Liab Total Assets

Taysha Gene balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Other Liab	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Cash And Short Term Investments	Retained Earnings Total Equity	Capital Surpluse	Property Plant And Equipment Gross	Non Current Liabilities Other
Total Assets		0.78	0.74	0.84	0.94	-0.74	0.78	0.85	0.79	0.48	0.93	0.88	0.75	0.96	0.99	0.94	0.73	0.72	0.71	0.65	-0.7	-0.7	0.44	-0.4	0.73	0.63
Other Current Liab	0.78		0.92	0.41	0.57	-0.73	1.0	0.44	0.86	0.39	0.93	0.72	0.91	0.59	0.7	0.53	0.84	0.99	0.87	0.98	-0.84	-0.84	0.3	-0.32	0.98	0.93
Total Current Liabilities	0.74	0.92		0.29	0.56	-0.89	0.93	0.52	0.96	0.54	0.92	0.85	0.99	0.52	0.67	0.48	0.96	0.92	0.99	0.85	-0.97	-0.97	0.41	-0.37	0.92	0.95
Total Stockholder Equity	0.84	0.41	0.29		0.93	-0.31	0.4	0.85	0.35	0.14	0.63	0.55	0.28	0.96	0.89	0.96	0.26	0.3	0.23	0.28	-0.21	-0.21	0.18	-0.18	0.31	0.19
Net Tangible Assets	0.94	0.57	0.56	0.93		-0.58	0.56	0.97	0.58	0.33	0.81	0.74	0.54	0.97	0.97	0.97	0.51	0.48	0.51	0.43	-0.52	-0.52	0.34	-0.36	0.49	0.46
Retained Earnings	-0.74	-0.73	-0.89	-0.31	-0.58		-0.77	-0.55	-0.94	-0.83	-0.81	-0.94	-0.92	-0.56	-0.7	-0.54	-0.96	-0.77	-0.94	-0.64	0.95	0.95	-0.59	0.57	-0.8	-0.76
Non Current Assets Total	0.78	1.0	0.93	0.4	0.56	-0.77		0.44	0.89	0.45	0.93	0.77	0.93	0.59	0.71	0.54	0.88	0.99	0.89	0.97	-0.86	-0.86	0.35	-0.34	0.99	0.92
Non Currrent Assets Other	0.85	0.44	0.52	0.85	0.97	-0.55	0.44		0.52	0.28	0.73	0.69	0.48	0.88	0.89	0.89	0.45	0.34	0.48	0.29	-0.5	-0.5	0.29	-0.31	0.35	0.42
Other Assets	0.79	0.86	0.96	0.35	0.58	-0.94	0.89	0.52		0.66	0.89	0.94	0.99	0.59	0.73	0.56	0.99	0.87	0.96	0.77	-0.95	-0.95	0.53	-0.38	0.89	0.84
Common Stock Shares Outstanding	0.48	0.39	0.54	0.14	0.33	-0.83	0.45	0.28	0.66		0.46	0.74	0.62	0.37	0.46	0.37	0.72	0.49	0.64	0.34	-0.69	-0.69	0.8	-0.81	0.53	0.39
Other Current Assets	0.93	0.93	0.92	0.63	0.81	-0.81	0.93	0.73	0.89	0.46		0.86	0.9	0.79	0.89	0.76	0.85	0.89	0.87	0.85	-0.86	-0.86	0.38	-0.38	0.89	0.87
Other Stockholder Equity	0.88	0.72	0.85	0.55	0.74	-0.94	0.77	0.69	0.94	0.74	0.86		0.88	0.75	0.85	0.74	0.92	0.72	0.86	0.59	-0.86	-0.86	0.62	-0.46	0.76	0.66
Total Liab	0.75	0.91	0.99	0.28	0.54	-0.92	0.93	0.48	0.99	0.62	0.9	0.88		0.53	0.68	0.49	0.99	0.92	0.99	0.84	-0.97	-0.97	0.48	-0.39	0.93	0.91
Net Invested Capital	0.96	0.59	0.52	0.96	0.97	-0.56	0.59	0.88	0.59	0.37	0.79	0.75	0.53		0.98	1.0	0.52	0.51	0.48	0.46	-0.47	-0.47	0.38	-0.35	0.53	0.4
Total Current Assets	0.99	0.7	0.67	0.89	0.97	-0.7	0.71	0.89	0.73	0.46	0.89	0.85	0.68	0.98		0.97	0.67	0.63	0.64	0.56	-0.63	-0.63	0.44	-0.4	0.65	0.55
Net Working Capital	0.94	0.53	0.48	0.96	0.97	-0.54	0.54	0.89	0.56	0.37	0.76	0.74	0.49	1.0	0.97		0.48	0.45	0.44	0.39	-0.44	-0.44	0.38	-0.35	0.47	0.35
Other Liab	0.73	0.84	0.96	0.26	0.51	-0.96	0.88	0.45	0.99	0.72	0.85	0.92	0.99	0.52	0.67	0.48		0.87	0.97	0.76	-0.97	-0.97	0.57	-0.44	0.9	0.84
Property Plant And Equipment Net	0.72	0.99	0.92	0.3	0.48	-0.77	0.99	0.34	0.87	0.49	0.89	0.72	0.92	0.51	0.63	0.45	0.87		0.89	0.98	-0.86	-0.86	0.37	-0.39	1.0	0.92
Net Debt	0.71	0.87	0.99	0.23	0.51	-0.94	0.89	0.48	0.96	0.64	0.87	0.86	0.99	0.48	0.64	0.44	0.97	0.89		0.81	-0.99	-0.99	0.44	-0.43	0.9	0.93
Accounts Payable	0.65	0.98	0.85	0.28	0.43	-0.64	0.97	0.29	0.77	0.34	0.85	0.59	0.84	0.46	0.56	0.39	0.76	0.98	0.81		-0.78	-0.78	0.25	-0.33	0.97	0.91
Cash	-0.7	-0.84	-0.97	-0.21	-0.52	0.95	-0.86	-0.5	-0.95	-0.69	-0.86	-0.86	-0.97	-0.47	-0.63	-0.44	-0.97	-0.86	-0.99	-0.78		1.0	-0.52	0.52	-0.87	-0.92
Cash And Short Term Investments	-0.7	-0.84	-0.97	-0.21	-0.52	0.95	-0.86	-0.5	-0.95	-0.69	-0.86	-0.86	-0.97	-0.47	-0.63	-0.44	-0.97	-0.86	-0.99	-0.78	1.0		-0.52	0.52	-0.87	-0.92
Retained Earnings Total Equity	0.44	0.3	0.41	0.18	0.34	-0.59	0.35	0.29	0.53	0.8	0.38	0.62	0.48	0.38	0.44	0.38	0.57	0.37	0.44	0.25	-0.52	-0.52		-0.8	0.41	0.28
Capital Surpluse	-0.4	-0.32	-0.37	-0.18	-0.36	0.57	-0.34	-0.31	-0.38	-0.81	-0.38	-0.46	-0.39	-0.35	-0.4	-0.35	-0.44	-0.39	-0.43	-0.33	0.52	0.52	-0.8		-0.41	-0.36
Property Plant And Equipment Gross	0.73	0.98	0.92	0.31	0.49	-0.8	0.99	0.35	0.89	0.53	0.89	0.76	0.93	0.53	0.65	0.47	0.9	1.0	0.9	0.97	-0.87	-0.87	0.41	-0.41		0.91
Non Current Liabilities Other	0.63	0.93	0.95	0.19	0.46	-0.76	0.92	0.42	0.84	0.39	0.87	0.66	0.91	0.4	0.55	0.35	0.84	0.92	0.93	0.91	-0.92	-0.92	0.28	-0.36	0.91

Click cells to compare fundamentals

Taysha Gene Account Relationship Matchups

Taysha Gene balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	258.9M	214.0M	126.3M	172.7M	198.6M	169.8M
Other Current Liab	5.1M	30.0M	16.8M	10.6M	12.2M	13.8M
Total Current Liabilities	7.1M	51.7M	62.8M	36.8M	42.3M	34.9M
Total Stockholder Equity	251.3M	95.4M	949K	74.9M	67.4M	67.6M
Retained Earnings	(61.1M)	(235.6M)	(401.4M)	(513.0M)	(461.7M)	(438.6M)
Non Current Assets Total	7.6M	54.4M	29.9M	22.9M	26.3M	25.2M
Non Currrent Assets Other	7.3M	1.1M	4.0M	2.5M	2.8M	3.3M
Common Stock Shares Outstanding	17.7M	37.7M	44.0M	116.1M	133.5M	140.2M
Liabilities And Stockholders Equity	258.9M	214.0M	126.3M	172.7M	198.6M	169.8M
Non Current Liabilities Total	450K	66.8M	62.5M	61.0M	70.2M	42.0M
Other Current Assets	6.6M	10.5M	8.5M	5.9M	6.8M	7.0M
Other Stockholder Equity	312.4M	331.0M	402.4M	587.9M	676.1M	359.6M
Total Liab	7.6M	118.6M	125.3M	97.8M	112.5M	76.9M
Net Invested Capital	251.3M	132.6M	38.9M	115.4M	132.8M	118.4M
Total Current Assets	251.3M	159.6M	96.4M	149.9M	172.3M	144.6M
Net Working Capital	250.8M	107.9M	33.6M	113.1M	130.1M	111.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Taysha Gene Therapies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taysha Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taysha Gene Therapies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taysha Gene Therapies Stock:

How To Invest In Taysha

Details

Is Taysha Stock a good investment?

Details

What is Taysha Gene's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.63

Revenue Per Share

0.042

Quarterly Revenue Growth

(0.62)

Return On Assets

(0.27)

Return On Equity

(1.15)

The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Taysha Historical Balance Sheet

About Taysha Balance Sheet Analysis

Taysha Gene Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Current Assets

Taysha Gene balance sheet Correlations

Taysha Gene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Taysha Gene balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Other Current Liab
Net Working Capital	+ 1.0	Net Invested Capital
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Other Current Liab

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.97	Other Liab
Cash	- 0.97	Other Liab
Cash And Short Term Investments	- 0.97	Total Liab
Cash	- 0.97	Total Liab